What are the key takeaways from this Pathfinders in Biopharma episode?

Key insights include: **Rally positioning:** Biotech is approximately in the "sixth inning" of its current rally, with the XBI still down 17% over five years versus the S&P 500 up 80%, meaning valuations are elevated but not bubble territory — investors should expect harder work finding alpha in 2026.; **M&A pipeline durability:** Big pharma faces $400 billion in revenue losses from patent cliffs over the next decade, and completed deals don't cover those gaps, signaling continued acquisition demand. M&A activity historically accelerates post-midterm elections, providing a structural tailwind for small and mid-cap biotech targets.; **Emerging innovation bets:** Protein degraders, in vivo CAR-T, and psychedelic-based therapies represent the highest-conviction breakthrough areas. Several psychedelic companies report Phase 3 data in H1 2026, potentially triggering a sharp re-rating of mental health treatment paradigms after single-administration remission results emerge.

What did Brian Abrams discuss on Pathfinders in Biopharma?

RBC Capital Markets analyst Brian Abrams assesses biotech's 80% rally from April 2025 lows, evaluating whether sector momentum can persist through 2026 amid rising valuations, regulatory uncertainty, M&A activity, and emerging innovation in obesity, psychedelics, and protein degraders. Key topics include: **Rally positioning:** Biotech is approximately in the "sixth inning" of its current rally, with the XBI still down 17% over five years versus the S&P 500 up 80%, meaning valuations are elevated but not bubble territory — investors should expect harder work finding alpha in 2026.; **M&A pipeline durability:** Big pharma faces $400 billion in revenue losses from patent cliffs over the next decade, and completed deals don't cover those gaps, signaling continued acquisition demand. M&A activity historically accelerates post-midterm elections, providing a structural tailwind for small and mid-cap biotech targets..

How long is this episode of Pathfinders in Biopharma?

This episode is 13 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Pathfinders in Biopharma

No biotech bubble – but can the sector’s rally persist through 2026?

January 27, 2026

13 min episode · 2 min read

Brian Abrams

Episode

13 min

Read time

2 min

Topics

Health & Wellness, Relationships, Investing

AI-Generated Summary

Published Mar 14, 2026

Key Takeaways

✓Rally positioning: Biotech is approximately in the "sixth inning" of its current rally, with the XBI still down 17% over five years versus the S&P 500 up 80%, meaning valuations are elevated but not bubble territory — investors should expect harder work finding alpha in 2026.
✓M&A pipeline durability: Big pharma faces $400 billion in revenue losses from patent cliffs over the next decade, and completed deals don't cover those gaps, signaling continued acquisition demand. M&A activity historically accelerates post-midterm elections, providing a structural tailwind for small and mid-cap biotech targets.
✓Emerging innovation bets: Protein degraders, in vivo CAR-T, and psychedelic-based therapies represent the highest-conviction breakthrough areas. Several psychedelic companies report Phase 3 data in H1 2026, potentially triggering a sharp re-rating of mental health treatment paradigms after single-administration remission results emerge.
✓SMID-cap leverage shift: Smaller biotechs have demonstrated successful independent drug launches, fundamentally changing negotiation dynamics in acquisition talks. Investors should reassess the traditional discount applied to pre-acquisition SMID-caps, as commercial self-sufficiency now generates standalone value without requiring big pharma partnership.

What It Covers

RBC Capital Markets analyst Brian Abrams assesses biotech's 80% rally from April 2025 lows, evaluating whether sector momentum can persist through 2026 amid rising valuations, regulatory uncertainty, M&A activity, and emerging innovation in obesity, psychedelics, and protein degraders.

Key Questions Answered

•Rally positioning: Biotech is approximately in the "sixth inning" of its current rally, with the XBI still down 17% over five years versus the S&P 500 up 80%, meaning valuations are elevated but not bubble territory — investors should expect harder work finding alpha in 2026.
•M&A pipeline durability: Big pharma faces $400 billion in revenue losses from patent cliffs over the next decade, and completed deals don't cover those gaps, signaling continued acquisition demand. M&A activity historically accelerates post-midterm elections, providing a structural tailwind for small and mid-cap biotech targets.
•Emerging innovation bets: Protein degraders, in vivo CAR-T, and psychedelic-based therapies represent the highest-conviction breakthrough areas. Several psychedelic companies report Phase 3 data in H1 2026, potentially triggering a sharp re-rating of mental health treatment paradigms after single-administration remission results emerge.
•SMID-cap leverage shift: Smaller biotechs have demonstrated successful independent drug launches, fundamentally changing negotiation dynamics in acquisition talks. Investors should reassess the traditional discount applied to pre-acquisition SMID-caps, as commercial self-sufficiency now generates standalone value without requiring big pharma partnership.

Notable Moment

Despite widespread fears, drug pricing policy proved far less damaging than anticipated — most companies resolved Most Favored Nation pricing concerns directly with the administration, and IRA Medicare discounting had minimal net pricing impact on revenues.

Know someone who'd find this useful?

Episode Transcript

Welcome back to Pathfinders, podcast series from RBC Capital Markets, where we explore the fast moving world of biotech and pharma. I'm your host, Joe Coletti. After a slower period following the COVID peak, biotech showed renewed momentum in 2025, supported by strong product launches, increased capital inflows, and positive investor sentiment. The sector made notable advances in areas like cancer vaccines, Alzheimer's therapies, and GLP one medications. The question now is whether 2026 will sustain this trajectory or if the most significant near term opportunities have already been captured. To help us answer some of these questions and dive into what 2026 could look like for biotech, I'm here with Brian Abrams, our head of global health care research, where he'll be talking about his report along with his team here at RBC Capital Markets. Brian, welcome back to the podcast. Thanks for having me. So biotech has staged an extraordinary comeback since the lows of last April with a wave of new drugs taking off and m and a values more than doubling across 2025. How far does this success story have left to run-in your view? Well, it's indeed been a tremendous run for the biotech space, with the sector now up 80% from its April lows. And like you said, Joe, there's a lot of good reasons for this. Launches have been strong. Capital inflows are spiking. Interest rates are coming down, which always helps the space, particularly the unprofitable smaller caps. Drug pricing spheres seem more manageable now, and m and a momentum looks poised to continue in the very near term. And, additionally, our checks suggest that investor sentiment is remaining favorable. But we do think we're probably in the sixth inning of this rally now As fundamental valuations have come up to levels that are generally a bit less compelling, regulatory volatility is likely to persist, and innovative areas are becoming more and more crowded. So while we still lean positively, we're probably a bit more balanced than some others out there. We do think intriguing opportunities still exist, but in 2026, investors are gonna need to look a bit harder in order to find them. Brian, we know that swelling valuations can trigger unease about a potential bubble. Do you believe the sector remains undervalued today, and what are the main potential risks in your forecast? Well, things have gotten more expensive. We don't think we're in a bubble. The XBI, a key sector index, has seen levels of around the one twenties before back in 2020 and 2021. And in in fact, it peaked around January 5. And over the past five years, even after this recent rally, the space is still down 17% versus the S and P being up 80%. So I think that helps put it into some context. Let's turn to the macroenvironment for a second. Macroeconomic factors such as tariffs, inflation, and interest rates have proved to be less disruptive to the sector than many originally …

Get the full transcript (2,214 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all Pathfinders in Biopharma transcripts →